Paul Schimmel Biography and Net Worth

Director of aTyr Pharma

Paul Schimmel, Ph.D. has served as a director since September 2005. Dr. Schimmel is currently a director of several private companies. He was a cofounder of Repligen Corporation, Alkermes, Inc., Cubist Pharmaceuticals, Sirtris Pharmaceuticals, and Alnylam Pharmaceuticals, Inc., and a founding Director of Momenta, Inc. Dr. Schimmel is a Professor of Molecular Medicine and of Chemistry at Scripps Research. He was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. Dr. Schimmel holds a B.A. from Ohio Wesleyan University and a Ph.D. in biochemistry and biophysics from the Massachusetts Institute of Technology. He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, the American Philosophical Society and the American Academy of Arts and Sciences.

What is Paul Schimmel's net worth?: The estimated net worth of Paul Schimmel is at least $906.46 thousand as of October 8th, 2025. Schimmel owns 1,095,024 shares of aTyr Pharma stock worth more than $906,461 as of December 4th. This net worth evaluation does not reflect any other investments that Schimmel may own. Learn More about Paul Schimmel's net worth.
How do I contact Paul Schimmel?: The corporate mailing address for Schimmel and other aTyr Pharma executives is 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on Paul Schimmel's contact information.
Has Paul Schimmel been buying or selling shares of aTyr Pharma?: During the last quarter, Paul Schimmel has bought $912,719.96 of aTyr Pharma stock. Most recently, on Thursday, October 9th, Paul Schimmel bought 317,999 shares of aTyr Pharma stock. The stock was acquired at an average cost of $0.94 per share, with a total value of $298,919.06. Following the completion of the transaction, the director now directly owns 1,413,023 shares of the company's stock, valued at $1,328,241.62. Learn More on Paul Schimmel's trading history.
Who are aTyr Pharma's active insiders?: aTyr Pharma's insider roster includes Jill Broadfoot (CFO), Nancy Denyes (General Counsel), Jane Gross (Director), and Paul Schimmel (Director). Learn More on aTyr Pharma's active insiders.
Are insiders buying or selling shares of aTyr Pharma?: In the last year, aTyr Pharma insiders bought shares 3 times. They purchased a total of 1,003,750 shares worth more than $927,719.96. In the last year, insiders at the sold shares 2 times. They sold a total of 2,153 shares worth more than $8,138.34. The most recent insider tranaction occured on October, 9th when Director Paul Schimmel bought 317,999 shares worth more than $298,919.06. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.
Information on this page was last updated on 10/9/2025.

Paul Schimmel Insider Trading History at aTyr Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/9/2025	Buy	317,999	$0.94	$298,919.06	1,413,023
10/8/2025	Buy	682,001	$0.90	$613,800.90	1,095,024
7/24/2024	Buy	52,300	$1.93	$100,939.00	413,023
7/22/2024	Buy	41,052	$1.74	$71,430.48	354,075

Paul Schimmel Buying and Selling Activity at aTyr Pharma

aTyr Pharma Company Overview

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Today's Range

Now: $0.83

$0.75

$0.86

50 Day Range

MA: $0.84

$0.65

$1.06

2 Week Range

Now: $0.83

$0.64

$7.29

Volume

3,226,154 shs

Average Volume

3,281,441 shs

Market Capitalization

$81.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57